How to control lymphangiogenesis: A novel role for rapamycin

被引：13

作者：

Kerjaschki, D. ^{[1
]}

机构：

[1] Univ Vienna, Allgemeines Krankenhaus, Dept Pathol, A-1090 Vienna, Austria

来源：

KIDNEY INTERNATIONAL | 2007年 / 71卷 / 08期

关键词：

D O I：

10.1038/sj.ki.5002184

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Analysis of the lymphatic microvasculature has become possible only recently by the discovery of novel proteins specifically expressed in lymphatic endothelial cells only. Therapeutic manipulation of de novo lymphangiogenesis might become clinically relevant in the future in diverse situations, such as renal transplant rejection. In this issue Huber et al. demonstrate that rapamycin acts as an efficient inhibitor of lymphangiogenesis.

引用

页码：717 / 719

页数：3

共 13 条

[11] Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected [J].

Stoeltzing, Oliver ;

Meric-Bernstam, Funda ;

Ellis, Lee M. .

CANCER CELL, 2006, 10 (02) :89-91

[12] Lymphatic neoangiogenesis in human renal allografts: Results from sequential protocol biopsies [J].

Stuht, S. ;

Gwinner, W. ;

Franz, I. ;

Schwarz, A. ;

Jonigk, D. ;

Kreipe, H. ;

Kerjaschki, D. ;

Haller, H. ;

Mengel, M. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (02) :377-384

[13] Is defective lymphatic drainage a trigger for lymphoid neogenesis? [J].

Thaunat, Olivier ;

Kerjaschki, Dontischo ;

Nicoletti, Antonino .

TRENDS IN IMMUNOLOGY, 2006, 27 (10) :441-445

← 1 2 →